Company: AEMD
Filing Date: 2025-02-12
Form Type: 10-Q
Source: 0001683168-25-000960
Chunk: 83

Company: AETHLON MEDICAL INC
Filing Date: 2025-02-12
Form: 10-Q
Item: Item 2
Chunk 83
---
,139 related to the acceleration of vesting
of stock options associated with the departure of our former Chief Executive Officer as well as expired or canceled employee stock options
and a $594,889 decrease resulting from a reduction in headcount. These reductions were partially offset by an increase of $346,566 in
separation expenses related to agreements with former executives. .

The $613,069 decrease in general and administrative
expenses was primarily driven by a $733,242 reduction in supplies, including raw materials and components required for manufacturing the
Hemopurifier, as well as laboratory materials for research and development. Additional reductions included an $84,583 decrease in insurance
expenses, a $48,725 decrease in repairs and maintenance primarily related to the cleanroom certification, a $27,779 reduction related
to travel and conferences, an $18,434 decrease in office supplies, a $17,529 decrease in depreciation. These decreases were partially
offset by a $317,616 increase in expenses primarily related to ongoing oncology clinical trials in Australia and India.

Net Loss

As a result of the changes in expenses noted above,
our comprehensive loss decreased from $9,778,234 in the nine months ended December 31, 2023, to $7,143,281 in the nine months ended December
31, 2024.

Basic and diluted loss attributable to common
stockholders was ($0.61) for the nine months ended December 31, 2024, compared to ($3.95) for the nine-month period ended December 31,
2023.

 23 

LIQUIDITY AND CAPITAL RESOURCES

As of December 31, 2024, we had a cash balance
of $4,825,387 and working capital of $3,194,737. This compares to a cash balance of $5,441,978 and working capital of $4,395,889 at March
31, 2024.

On May 17, 2024, we closed a public offering of
our equity, pursuant to which we sold an aggregate of: (i) 2,450,000 shares of our common stock and accompanying Class A warrants to purchase
up to 2,450,000 shares of common stock and Class B warrants to purchase up to 2,450,000 shares of common stock, at a combined public offering
price of $0.58 per share and accompanying warrants; and (ii) in lieu of common stock,